Form4insider filings, from the source

SEC Form 4 · accession 0001615774-18-006729

Crinetics Pharmaceuticals, Inc. · CRNX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
Period of report
Jul 20, 2018
Accepted (ET)
Jul 20, 2018 · 4:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001658247

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2,F5Jul 20, 2018C2,560,613—A2,560,613ISee Footnote
Common StockF1,F3,F5Jul 20, 2018C353,590—A353,590ISee Footnote
Common StockF1,F2,F5Jul 20, 2018C413,040—A2,973,653ISee Footnote
Common StockF1,F3,F5Jul 20, 2018C57,035—A410,625ISee Footnote
Common StockF2,F5Jul 20, 2018P51,686$17.00A3,025,339ISee Footnote
Common StockF3,F5Jul 20, 2018P7,137$17.00A417,762ISee Footnote
Common StockF4,F6Jul 20, 2018P141,177$17.00A141,177ISee Footnote
Common StockF7,F4,F6Jul 20, 2018P153,180$20.73A294,357ISee Footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Series A Preferred StockF1,F2,F5—Jul 20, 2018C8,424,416D——Common Stock2,560,6130I
Series A Preferred StockF1,F3,F5—Jul 20, 2018C1,163,311D——Common Stock353,5900I
Series B Preferred StockF1,F2,F5—Jul 20, 2018C1,358,903D——Common Stock413,0400I
Series B Preferred StockF1,F3,F5—Jul 20, 2018C187,648D——Common Stock57,0350I

Explanation of responses